IADR Abstract Archives
Effects of Alpha-Lactalbumin Hydrolysate on Human Squamous Cell Carcinoma Cells
Objectives: Squamous cell carcinoma (SCC) is a common malignant tumor found in the oropharyngeal region. Alpha-lactalbumin hydrolysate (LAH), a main component found in whey protein, has shown cytotoxicity against several cancer cells and holds promise as an alternative anti-cancer agent. However, the effects of LAH on head and neck cancer cells remain elusive. This study aims to examine the effects of LAH on the behavior of SCC cell lines, in vitro.
Methods: The primary and metastatic human tongue SCC cell lines (HSC-4 and 7) and pharyngeal SCC cell lines (HN-22, 30 and 31) were treated with a 2-fold serial dilution of LAH (100-0.39 mg/ml). Cell viability and cell proliferation were investigated using the MTT assay. Cell migration was examined using the scratch wound healing assay. Gene expression of matrix metalloproteinases (MMP) and tissue inhibitor of metalloproteinases (TIMP) was assessed using RT-qPCR. All statistical analyses were evaluated at p value <0.05.
Results: LAH treatment at 25, 50, and 100 mg/ml exhibited cytotoxicity on all HSC and HN cells, as well as immortal human PDL cells. The proliferation of HSC and HN cells was also significantly attenuated after LAH treatment from day 3. Further, LAH treatment inhibited cancer cell migration in both primary and metastatic HSC and HN cells. The mRNA expression of MMP1 and MMP2 was significantly downregulated in the HN-22 cell. Similarly, the expression of MMP1 and MMP13 transcript was reduced in HSC-4 cell, while mRNA level of MMP2 and TIMP1 was downregulated in HSC-7 cell.
Conclusions: LAH treatment has inhibitory effects on cancer cell proliferation and migration in HSC and HN cell lines, in vitro. This suggests the promising activity of LAH as an alternative anti-cancer agent; however, further investigation is required.
Methods: The primary and metastatic human tongue SCC cell lines (HSC-4 and 7) and pharyngeal SCC cell lines (HN-22, 30 and 31) were treated with a 2-fold serial dilution of LAH (100-0.39 mg/ml). Cell viability and cell proliferation were investigated using the MTT assay. Cell migration was examined using the scratch wound healing assay. Gene expression of matrix metalloproteinases (MMP) and tissue inhibitor of metalloproteinases (TIMP) was assessed using RT-qPCR. All statistical analyses were evaluated at p value <0.05.
Results: LAH treatment at 25, 50, and 100 mg/ml exhibited cytotoxicity on all HSC and HN cells, as well as immortal human PDL cells. The proliferation of HSC and HN cells was also significantly attenuated after LAH treatment from day 3. Further, LAH treatment inhibited cancer cell migration in both primary and metastatic HSC and HN cells. The mRNA expression of MMP1 and MMP2 was significantly downregulated in the HN-22 cell. Similarly, the expression of MMP1 and MMP13 transcript was reduced in HSC-4 cell, while mRNA level of MMP2 and TIMP1 was downregulated in HSC-7 cell.
Conclusions: LAH treatment has inhibitory effects on cancer cell proliferation and migration in HSC and HN cell lines, in vitro. This suggests the promising activity of LAH as an alternative anti-cancer agent; however, further investigation is required.